Timing of surgery in Barlow disease.
Author(s) -
Carlo Rostagno,
Ginevra Droandi,
Alessandra Rossi,
Sergio Bevilacqua,
Stefano Romagnoli,
Gian Franco Montesi,
Pier Luigi Stefáno
Publication year - 2015
Publication title -
italian journal of anatomy and embryology = archivio italiano di anatomia ed embriologia
Language(s) - English
Resource type - Journals
ISSN - 2038-5129
DOI - 10.13128/ijae-16467
Dear Sir, Timing of surgery in chronic mitral valve regurgitation has been a long term matter of debate. Data from European Society of Cardiology suggest that a number close to 36 % of surgical treatment in mitral valve regurgitation is performed too early or too late according to guidelines suggestions (Iung et al., 2003). Bileaflet mitral valve prolapse (Barlow’s disease) as correctly reported in the letter by Yiginer et al (Tiginer et al., 2015) may be part of a more complex disease which involves not only mitral leaflets but also fibrous skeleton of the heart leading to a disproportionate increase of left ventricular volumes in absence of severe mitral regurgitation. Thus end systolic volume may be a misleading factor to indicate surgery in this setting of patients . However in patients included in our study mitral valve regurgitation was severe in all patients, average EROA (cm2) was 0.58±0.26 [range 0.25-1.6], 27 patient had persistent or previous episodes of atrial fibrillatio , flail of one of the two leaflets was present in 40 (8 anterior mitral leaflet , 32 posterior mitral leaflet), severe pulmonary hypertension was present in 40%. As suggested by ESC guidelines (Vahanian et al., 2012), in patients at low operative risk, where there is a high likelihood of durable valve repair on the basis of experience of the surgeon, early intervention is justified to halt progression of disease. Atrial fibrillation, pulmonary hypertension and severe anatomic damage (flail) of the leaflets should be considered for surgery despite normal end systolic volume and normal left ventricular ejection fraction. Furthermore successful treatment of AF may obtained with associated radiofrequency ablation (Rostagno et al., 2013). In conclusion in a high activity volume hospital, mitral valve repair may be performed in patients with Barlow’s disease to correct severe anatomic damage of the valve leaflets, to halt progression of hemodynamic changes and to treat or prevent atrial fibrillation before left ventricular dysfunction occur .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom